Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment.
Shargall
Yaron
Y
Division of Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada.
Guenther
Grisha
G
Ahya
Vivek N
VN
Ardehali
Abbas
A
Singhal
Arun
A
Keshavjee
Shaf
S
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000990:Antithrombin III / Q000037:antagonists & inhibitors; D015199:Extracorporeal Membrane Oxygenation; D005440:Fluid Therapy; D016166:Free Radical Scavengers / Q000008:administration & dosage; D006801:Humans; D008171:Lung Diseases / Q000209:etiology / Q000628:therapy*; D016040:Lung Transplantation / Q000009:adverse effects*; D020782:Matrix Metalloproteinases / Q000008:administration & dosage; D009569:Nitric Oxide / Q000008:administration & dosage; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011182:Postoperative Care; D011453:Prostaglandins / Q000008:administration & dosage; D011663:Pulmonary Surfactants / Q000008:administration & dosage; D011951:Receptors, Complement / Q000008:administration & dosage; D012086:Reoperation; D015427:Reperfusion Injury / Q000209:etiology / Q000628:therapy*; D012121:Respiration, Artificial
D000806:Angiotensin-Converting Enzyme Inhibitors; D016166:Free Radical Scavengers; D010972:Platelet Activating Factor; D011453:Prostaglandins; D011663:Pulmonary Surfactants; D011951:Receptors, Complement; C082885:soluble complement inhibitor 1; D009569:Nitric Oxide; D000990:Antithrombin III; D020782:Matrix Metalloproteinases